Alternative sources are urgently needed to fulfill the severe shortfall in human-donated organs, such as hearts. Xenotransplantation promises a potentially unlimited supply. However, the necessary techniques are complicated and potentially risky. Thus, it has been decided that only experienced groups should attempt the first clinical trials, and these should be strictly controlled by the national and international regulatory authorities. Key issues include the means of ensuring microbiologic safety and evaluating the efficacy of the transplants in a relevant pre-clinical model.
|